Kuaihua Pharmaceutical, a longstanding leader in China’s pediatric medicine market, has reported its first annual loss since going public 11 years ago. The 2025 annual report, released in late April, paints a grim picture of a company struggling to navigate what it calls an "unprecedented depth of adjustment" within the traditional pharmaceutical manufacturing sector. The firm, famous for its 'Little Sunflower' brand, saw its total revenue drop by over 31% to 2.318 billion RMB, while net profit plummeted by a staggering 152% into negative territory.
This fiscal collapse marks a dramatic reversal from the company’s performance just two years prior. In 2023, Kuaihua reached its historical peak, generating 5.7 billion RMB in revenue and over 1.1 billion RMB in net profit. However, the momentum vanished by 2024 as the industry faced a severe restructuring of the competitive landscape. Management admitted that a strategic lag in responding to high inventory levels across downstream channels left the company vulnerable to the current downturn.
The decline was particularly pronounced in the company's core Traditional Chinese Medicine (TCM) segment, which saw revenues shrink by 38.4%. Despite the massive contraction in sales, Kuaihua significantly increased its promotional spending, with sales expenses rising nearly 35% to 580 million RMB. This aggressive marketing push stood in stark contrast to the company’s investment in innovation; research and development spending was slashed by more than 10% during the same period.
Compounding the financial concerns is a high-profile leadership transition that reinforces the company's dynastic governance. Just weeks before the disastrous earnings report, Guan Yi—the daughter of actual controller Guan Yanbin—was appointed as Vice Chairwoman. Guan Yi, who has been with the firm since 2002, joins her sister, Chairwoman Guan Yuxiu, at the helm of the family-controlled enterprise. The reshuffle suggests that even as the company faces its greatest financial challenge, the Guan family is tightening its grip on executive power.